Greenwich LifeSciences, Inc. (GLSI) vs Lexeo Therapeutics, Inc. Common Stock (LXEO)
A side-by-side comparison of Greenwich LifeSciences, Inc. and Lexeo Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
GLSI
Greenwich LifeSciences, Inc.
$15.79HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
LXEO
Lexeo Therapeutics, Inc. Common Stock
$3.30HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — GLSI vs LXEO
growth of $100 · dividends reinvested · last 3yGLSI +86.9% (+23.2%/yr)LXEO -66.1% (-30.3%/yr)GLSI compounded faster over this window
Log scale — wide-divergence pair
GLSI LXEO
GLSI vs LXEO: by the numbers
- •LXEO is the larger company ($259M vs $232M market cap).
Metrics side by side
Valuation
| Metric | GLSI | LXEO |
|---|---|---|
| P/B ratio | 74.36 | 1.10 |
Profitability
| Metric | GLSI | LXEO |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% |
| ROE | -695.56% | -37.12% |
| ROIC | -701.55% | -39.76% |
Growth (annualized)
| Metric | GLSI | LXEO |
|---|---|---|
| Total return CAGR (5Y) | -14.84% | N/A |
Go deeper
Dig into the metrics
Greenwich LifeSciences ROELexeo Therapeutics, Inc. Common Stock ROEGreenwich LifeSciences operating marginLexeo Therapeutics, Inc. Common Stock operating marginGreenwich LifeSciences revenue growthLexeo Therapeutics, Inc. Common Stock revenue growthGreenwich LifeSciences free cash flowLexeo Therapeutics, Inc. Common Stock free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.